| First Author | Lin Z | Year | 2022 |
| Journal | Cancers (Basel) | Volume | 14 |
| Issue | 19 | PubMed ID | 36230562 |
| Mgi Jnum | J:330139 | Mgi Id | MGI:7365361 |
| Doi | 10.3390/cancers14194640 | Citation | Lin Z, et al. (2022) Lin28 Regulates Cancer Cell Stemness for Tumour Progression. Cancers (Basel) 14(19) |
| abstractText | Tumours develop therapy resistance through complex mechanisms, one of which is that cancer stem cell (CSC) populations within the tumours present self-renewable capability and phenotypical plasticity to endure therapy-induced stress conditions and allow tumour progression to the therapy-resistant state. Developing therapeutic strategies to cope with CSCs requires a thorough understanding of the critical drivers and molecular mechanisms underlying the aforementioned processes. One such hub regulator of stemness is Lin28, an RNA-binding protein. Lin28 blocks the synthesis of let-7, a tumour-suppressor microRNA, and acts as a global regulator of cell differentiation and proliferation. Lin28also targets messenger RNAs and regulates protein translation. In this review, we explain the role of the Lin28/let-7 axis in establishing stemness, epithelial-to-mesenchymal transition, and glucose metabolism reprogramming. We also highlight the role of Lin28 in therapy-resistant prostate cancer progression and discuss the emergence of Lin28-targeted therapeutics and screening methods. |
